Could a third chemo drug tame advanced endometrial cancer?
NCT ID NCT06102252
First seen May 28, 2026 · Last updated Jun 19, 2026 · Updated 6 times
Summary
This study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before surgery. The main goal was to see how many patients could complete all six cycles of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sohag university Hospital
Sohag, Sohag, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel, carboplatin, and epirubicin (chemotherapy drugs)
What this could lead to
If adding epirubicin works better, it could improve how well chemotherapy shrinks advanced endometrial cancer before surgery.
What could go wrong
This is a small, completed study with only 60 participants. Adding epirubicin may increase side effects without clear benefit, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.